Dapoflit Trio 1 Tablet is a scientifically formulated triple-drug oral therapy combining Dapagliflozin 10mg, Glimepiride 1mg, and Metformin 500mg, designed to provide comprehensive blood glucose control in patients with type-2 diabetes mellitus.
Dapagliflozin supports glucose excretion through the kidneys, Glimepiride enhances insulin secretion, and Metformin improves insulin sensitivity while reducing hepatic glucose output. This complementary mechanism helps control both fasting and postprandial blood sugar levels effectively.
The lower-dose Glimepiride and Metformin strengths make this combination suitable for early to moderate-stage diabetic patients who require triple therapy without excessive hypoglycemia risk. It is commonly prescribed by physicians and diabetologists for long-term metabolic control.
Adding Dapoflit Trio 1 Tablet to your range strengthens your diabetes and chronic-care segment, opening opportunities in retail pharmacy supply, hospital procurement, institutional distribution, export markets, and third-party manufacturing. Its balanced formulation and high prescription relevance make it a commercially strong product.